NCT03586128 - Partners PrEP Program | Biotech Hunter

Enrollment

1,381

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions

HIV Infections

Interventions

DRUG

PrEP

PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.

DRUG

ART

ART medication will be provided according to Uganda national guidelines for persons living with HIV.

Trial Locations (1)

Unknown

Makerere University, Kampala

All Listed Sponsors

collaborator

Harvard University

OTHER

collaborator

Makerere University

OTHER

lead

University of Washington

OTHER